Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18240015 | 0.86 | TSHR (0.37) | TSHRSLC1A3SLC1A2SLC1A1ACHE | |
| SCHEMBL17268908 | 0.82 | TSHR (0.32) | TSHR | |
| Hydrochloric Acid SCHEMBL17256300 | 0.80 | TSHR (0.31) | TSHR | |
| SCHEMBL379087 | 0.78 | TSHR (0.35) | TSHRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL25763454 | 0.74 | POLB (0.41) | TSHR | |
| SCHEMBL17934072 | 0.74 | MEN1 (0.39) | TSHR | |
| SCHEMBL26131627 | 0.72 | TSHR (0.44) | TSHRSLC1A3SLC1A2SLC1A1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL27947517 | 0.71 | HRH4 (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL9618064 | 0.70 | GSTP1 (0.35) | TSHRSLC1A3SLC1A2SLC1A1ACHE | |
| SCHEMBL18373147 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3145934-B1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180296585-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3373979-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | Pfizer Inc (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10039778-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2017083368-A9 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | PFIZER INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20170165284-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
| WO-2017083368-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | PFIZER INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| US-9617293-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160207953-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2016-07-21 | — | — | US | disclosed |
| US-9340553-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207953-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | TSHR 319/4885SLC1A3 1654/4885SLC1A2 1603/4885 |
| US-20170165284-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | TSHR 319/4885SLC1A3 1654/4885SLC1A2 1603/4885 |
| US-20150329555-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | TSHR 319/4885SLC1A3 1654/4885SLC1A2 1603/4885 |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | TSHR 319/4885SLC1A3 1654/4885SLC1A2 1603/4885 |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | TSHR 823/4885SLC1A3 3855/4885SLC1A2 3636/4885 |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | TSHR 319/4885SLC1A3 1654/4885SLC1A2 1603/4885 |
| US-20180296585-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | TSHR 319/4885SLC1A3 1654/4885SLC1A2 1603/4885 |
| US-10039778-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | TSHR 319/4885SLC1A3 1654/4885SLC1A2 1603/4885 |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | TSHR 319/4885SLC1A3 1654/4885SLC1A2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.